NCT06765252View on ClinicalTrials.gov

Effect of Genetic Polymorphism on Capecitabine-Induced Toxicity in Egyptian Cancer Patients

RecruitingOBSERVATIONAL
Enrollment

80

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

April 30, 2025

Study Completion Date

August 31, 2025

Conditions
Colorectal CancerBreast Cancer
Interventions
DRUG

Capecitabine-based chemotherapy

Participants receiving capecitabine in an oral dose of 1,000-1,250 mg/m2 twice daily for the first 14 days of each 21-day cycle.

Trial Locations (1)

32511

RECRUITING

Department of Clinical Oncology, Faculty of Medicine, Menoufia University, Shibīn al Kawm

All Listed Sponsors
collaborator

Menoufia University

OTHER

lead

Ain Shams University

OTHER